Innoviva
Update in progressINVA (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Innoviva, Inc. is a biopharmaceutical company with a global royalties portfolio. It markets RELVAR/BREO ELLIPTA (vilanterol and fluticasone furoate) and ANORO ELLIPTA (umeclidinium and vilanterol) for COPD and asthma. It also sells GIAPREZA, XACDURO, XERAVA, ZEVTERA, and NUZOLVENCE, and develops bacteriophages. Partnerships include Sarissa Capital and Glaxo Group Limited. Formerly Theravance; renamed in 2016. Founded 1996; based in Burlingame, California.
Company score
- Sentiment
- 0.51
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.69
- Governance
- 0.14
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.24
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.37
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Pavel Raifeld C.F.A.
- Founded1996
- Employees159
- Websitewww.inva.com
Identifiers
- ISINUS45781M1018
- FIGIBBG000CG9XT7
- LEI549300ACOX4QTBES6535
- CUSIP45781M101
- CIK0001080014